February 21, 2017 7:51am

 

Promises, promises – how many CEOs have kept their word to Investors …

NONE and one – more dilution

 

Anyone who reads my posts, knows that I am about making money, no matter what happens in the sector

Today’s headlights: Dow futures are UP +0.34% and NASDAQ futures are UP +0.27%

 

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

 

Companies in my headlights, the 4 B’s – BCLM, BSTG, BTX and BCLI; which are BUYS and which one is a strong SELL

 

 

Expectation will be the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions through this year 2017.

 

 

Indexes and ETFs: The IWM (+0.22%) whiles the IBB, XBI and XLV is NOT indicating

 

U.S. stock index futures were poised for a higher open on Tuesday as traders eyed a deluge of earnings reports on the first trading day of the week.

European markets recovered from earlier losses to edge higher in mid-morning trade as investors focused on company earnings and fresh economic data.

Asia markets traded mixed, as some traders expected continued support from the optimism around President Donald Trump's economic policies, which sent global stocks higher in recent weeks.

 

Data docket: will see flash Markit services PMI (Purchasing Managers' Index) for February released at 9.45 a.m. ET.

 

BUY: BLCI, BLCM, BTX

SELL: BSTG

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) closed POSITIVE on Friday, NEGATIVE Thursday and POSITIVE on Wednesday and last Tuesday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

·         Monday, the market was closed;

·         Friday closed POSITIVE with 17 decliners, 21 advancers and 5 flats;

·         Thursday closed NEGATIVE with 26 decliners, 16 advancers and 1 flat;

·         Wednesday closed POSITIVE with 15 decliners, 25 advancers and 3 flats;

·         Last Tuesday closed POSITIVE with  20 decliners, 21 advancers and 2 flats;

 

 

Remembering Friday’s closing bell newsletter, “The daily roulette wheel spun.  The money ball dropped in the short-term momentum pocket.”

  • Reiterating, “The payout odds like the market of sector stocks for betting are based on probability – so what is different …?”

As further Q4/16 financial results are released, we will see the fragility of the sector.

  • That fragility is further enhanced by those who will attempt to force their way through the capital market open window for financing.

The problem is the capital access is getting lower every session. 

 

One “named” failure will set the tone for other companies to right-side their focus to investors; we at the moment are too dependent on bottom-feeding warrant clippers for investment.

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

·         The iShares Nasdaq Biotechnology (IBB) closed  Friday up +0.47% and is NOT Indicating in Tuesday’s pre-market;

·         The SPDR S&P Biotech ETF (XBI) closed Friday up +1.01% and is NOT indicating Tuesday’s after-market;

·         The Health Care Select Sector SPDR ETF (XLV) closed up +0.14% Friday and NOT indicating in Tuesday’s pre-market;

·         The iShares Russell 2000 (IWM) closed down -0.09% on Friday and is UP +0.22% in Tuesday’s pre-market

                                                                                   

 

Companies in my headlights:

 

Bellicum Pharma (BLCM) closed UP +$0.11 to $13.62. BLCM has dosed the first patient with BPX-601, the first CAR T-cell product candidate to enter clinical studies that is designed to enable control over the expansion and stimulation of the cells. BPX-601 targets solid tumors that express PSCA (prostate stem cell antigen), with an initial indication in non-resectable pancreatic cancer. I believe the initiation of the BPX-601 clinical study is an important milestone in the advancement of CAR T therapies – BUY;

Biostage (BSTG) closed DOWN -$0.0055 to $0.335 after a $0.40 share offering that reaped a measly $8 M. - hopefully enough money to last them to next February but, they do have new offices and a brand new cafeteria costing $100 K that investors have just payed for with $0.30 stock.  BSTG will stay under $0.40 as “bottom feeders” sell the stock and keep the warrants. Consider $0.25 as a resting spot as an IND is still NOT finalized for submittal in Q3/17- Strong SELL;

BioTime (NYSEMKY: BTX) closed FLAT at $2.97. BioTime announced the deconsolidation of OncoCyte <a subsidiary> financial statements from its statements effective February 17 with BTX reporting a pro forma, non-cash gain of approx. $56 M – BUY; 

Brainstorm Cell therapy (BCLI) closed UP +$0.08 to $3.60. BCLI has signed an agreement with CCRM, a Toronto-based leader in developing and commercializing regenerative medicine technologies, and cell and gene therapies, to support the market authorization request for NurOwn®.   At this time, CCRM is helping Brainstorm explore the opportunity to access Health Canada's early access pathway for treatment of patients with Amyotrophic Lateral Sclerosis (ALS).  If NurOwn® qualifies for Health Canada's "Notice of Compliance with Conditions" pathway; it could be authorized in Canada for distribution in early 2018 - BUY

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.